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Change is coming to how healthcare is delivered in the United 
States.  Millennials, and the generations that will follow, have entirely 
novel expectations about how services need to be delivered – namely 
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that they be efficient, and cost-effective.  Unfortunately, the traditional 
healthcare delivery model is simply incompatible with these needs.  
This is due in part to the shortfalls of current regulatory structures, and 
the complexities of the healthcare marketplace generally.  Huge tech 
companies have taken note of new demands resulting from the 
dissonance between our healthcare system, the market for its current 
service structure, and the deleterious effects of federal regulations.  
Targeting to the needs of the emerging, tech-dependent generations, 
and exploiting regulators’ and healthcare institutions’ failure to adapt, 
big tech is on a path to consolidating an essentially unregulated method 
of healthcare delivery – direct-to-consumer goods and services.  This 
article examines the inevitable shifts in healthcare markets that are to 
come, and touches on areas that regulators have – as yet – failed to take 
proactive measures. By examining current and past shortfalls in 
healthcare regulation, this article illuminates imminent issues that need 
to be addressed by considered legislation.  The healthcare industry has 
a lot to lose if giant tech companies consolidate healthcare delivery 
markets before some action is taken – the time for such action is now. 
INTRODUCTION 
It’s Sunday morning and you wake with a pain in the back of your 
throat.  While putting on a pot of tea, you enter your symptoms 
including fever and elevated white blood cell count, per your 
smartwatch, into an app.  Before the tea kettle steams, you are 
discussing your sore throat with a provider, and one hour later a 
treatment pack arrives at your doorstep.  Can you imagine a world like 
this, where you could receive healthcare on demand, at your 
convenience, without leaving your own home?  Amazon and Google 
can, in fact, six of the largest companies in the world are betting billions 
that you can.1 
Healthcare is likely to become the next industry revolutionized by 
the Millennial consumer, just as other traditional purchase models have 
adapted to meet the growing change in consumer expectations.  Big 
tech’s recent involvement in the healthcare industry suggests such a 
                                                          
1. In 2018 alone, Amazon, Apple, Berkshire-Hathaway, JPMorgan Chase, and 
Google invested billions in major health initiatives. Robert Pearl, Why Did Google 
Hire Geisinger CEO Dr. David Feinberg, FORBES (Nov. 10, 2018, 8:42 AM), 
https://www.forbes.com/sites/robertpearl/2018/11/10/google/#2558a2 d242c0.   
2
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looming disruption of the current healthcare delivery model; however, 
the traditional healthcare industry is inapposite to a developing “direct-
to-consumer healthcare” approach where companies are born online 
and sell directly to their customers, effectively eliminating the need for 
a storefront.2  In the case of healthcare, a direct-to-consumer model 
eliminates much of existing traditional healthcare delivery in hospitals 
and face-to-face visits. 
Considered the first digitally native generation, Millennials3 have  
unique expectations of technology that differ from any preceding 
generation.4  Unlike Baby Boomers5 and GenXers,6 Millennials expect 
technology to be readily available and efficiently meet most of their 
needs.7  Consequently, this dependence on technology has adjusted the 
Millennial perception of services and Millennials display entirely new 
patterns of social and purchasing behavior.8  Most industries have 
                                                          
2. Adele Chapin, What is the Direct-to-Consumer Sales Model and Why Should 
you Care, RACKED (Aug. 11, 2016, 10:02 AM), https://www.racked.com/2016/8/11/ 
12412470/direct-to-consumer-sales-explainer (explaining the recent development of 
the direct-to-consumer business model).   
3. Based on a July 1, 2017 census, there are 30.6 million millennials in the 
United States, accounting for over 23% of the population.  So How Many Millennials 
Are There in the US, MARKETING CHARTS (Apr. 30, 2018), https://www.marketing 
charts.com/featured-30401 [hereinafter How Many Millennials]. 
4. Micah Solomon, For Small Businesses Week: All About Millennial 
Consumers and Millennial-Friendly Customer Experiences, FORBES (May 3, 2018, 
9:26 PM), https://www.forbes.com/sites/micahsolomon/2018/05/03/for-small-busin 
ess-week-all-about-millennial-consumers-and-millennial-friendly-customer-experien 
ces/#648644292f91. 
5. Baby Boomers are those born between the mid-1940s to the 1960s. Anna 
Johnston, Gen When?, THE SUN (May 25, 2018, 3:00 PM), https://www.thesun. 
co.uk/fabulous/5505402/millennials-baby-boomers-generation-groups-z-y-x-explain 
ed/.  
6. GenXers are those born between the mid-1960s and the early 1980s. Id.  This 
generation is savvy, skeptical, self-reliant, and known for its work ethic. Paul Taylor 
& George Gao, Generation X: America’s Neglected ‘Middle Child’, PEW RES. 
CENTER (June 5, 2014), http://www.pewresearch.org/fact-tank/2014/06/05/generatio 
n-x-americas-neglected-middle-child.  
7. Solomon, supra note 4. 
8. Maxime Rieman, Insurance Companies Need to Adjust Product and 
Approach to Address Millennials, FORBES (Jan. 5, 2018, 8:30 AM), https://www.for 
bes.com/sites/forbesbusinessdevelopmentcouncil/2018/01/05/insurance-companies-
need-to-adjust-product-and-approach-to-address-millennials/#3fdc01a87a4d.  
3
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embraced these shifts in an effort to capture the disposable income of 
the population’s largest generation. 
Traditional service industries have redefined delivery methods and 
identified marketing strategies to provide constant, continuous, and 
convenient access to their products, knowing they will profit 
significantly from Millennials.  But the traditional healthcare industry 
has failed to keep pace, and Millennials are, perhaps consequently, the 
least likely to seek medical treatment.  Possibly due to high cost and 
general inconvenience, Millennials are driven to a familiar marketplace 
that meets their healthcare needs on demand: online platforms and 
direct-to-consumer health products.  Contrary to the traditional model, 
these alternatives provide answers in real time, for next-to-no cost. 
This article examines legal shortfalls in the United States as they 
relate to this shift in healthcare delivery, driven by Millennials, to 
direct-to-consumer medicine.  Part I of this article will review the 
business of healthcare, focusing on the current delivery model and its 
recent incorporation of technology.  Part II will examine forms of 
direct-to-consumer medicine, focusing on direct-to-consumer 
advertising and the direct-to-consumer health products available today.  
Part III will discuss possible strategies to protect the patient-consumer 
during this shift in healthcare delivery to direct-to-consumer medicine, 
assessing first a retroactive response and finally proactive reform.  This 
article will conclude by highlighting the imminent need for institutions 
and regulators to address these changes before the face of healthcare is 
changed forever – to the detriment of the healthcare industry. 
I. THE BUSINESS OF HEALTHCARE 
Healthcare is one of the largest industries in the United States, 
employing approximately 13,000,000 American workers,9 and 
accounting for nearly 18% of the GDP.10  Interestingly, healthcare is a 
                                                          
9. Total Health Care Employment, HENRY J. KAISER FAM. FOUND., 
https://www.kff.org/other/state-indicator/total-health-care-employment (last visited 
May 1, 2019).  
10. D. Yoni Blumberg, Here’s the Reason Health Care Costs So Much More in 
the US, CNBC (Mar. 22, 2018, 11:37 AM), https://www.cnbc.com/2018/03/22/the-
real-reason-medical-care-costs-so-much-more-in-the-us.html (citing Irene Papani-
colas, Liana Woskie & Ashish Jha, Health Care Spending in the United States and 
Other High-Income Countries, 39 JAMA 1024 (2018)). 
4
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social need, yet simultaneously an extremely lucrative business.  Like 
other industries, healthcare is a service.  What makes healthcare unlike 
most industries, however, is that it provides a service that is not only 
essential to society, but also operates based on individually specified 
needs.  For example, a patient does know when they will be diagnosed 
with cancer or hit by a car and require care.  Consequently, in an effort 
to ensure Americans have the ability to obtain healthcare when it is 
required, legislatures place extensive regulations on the industry at the  
state and federal level.11  Unfortunately, some of these regulations 
inhibit the healthcare industry’s ability to incorporate changing societal 
and consumer expectations driven by the emergence of the Millennial 
consumer cohort. 
A. The Current Healthcare Model 
The United States notoriously over-spends on healthcare, with 
costs nearly double those of comparable industrialized countries.12  
Despite having the most expensive medical care in the world, the 
United States’ healthcare system is the worst-performing of eleven 
developed countries – including Canada, France, Germany, and the 
U.K. – in terms of access, efficiency, and equity.13 
Healthcare delivery in the U.S. is an anomaly among developed 
countries in that it operates mostly through private hospitals and 
physician-negotiated fee structures.14  Pricing is thus largely 
unconstrained, resulting in rising costs of medication, medical services, 
and hospital administration.15  Treatment compensation levels are also 
                                                          
11. Needless to say, the number of healthcare regulations that effect the market 
vast; thus, this comment will not address most of the complexities of healthcare 
regulation. 
12. In 2016, the United States spent 17.8% of its GDP on health care, 
meanwhile, the average spending of ten other high-income countries (Canada, 
Germany, Australia, the U.K,. Japan, Sweden, France, the Netherlands, Switzerland, 
and Denmark) was only 11.5%. Blumberg, supra note 10. 
13. Olga Khazan, U.S. Healthcare: Most Expensive and Worst Performing, THE 
ATLANTIC (June 16, 2014), https://www.theatlantic.com/health/archive/2014/06/us-
healthcare-most-expensive-and-worst-performing/372828.  
14. Arthur Daemmrich, U.S. Healthcare Reform and the Pharmaceutical 
Industry 4 (Working Paper 12-015 Sept. 14, 2011), https://www.hbs.edu/faculty/Publ 
ication%20Files/12-015.pdf. 
15. Blumberg, supra note 10. 
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largely driven by Medicare reimbursement rates, which are set by the 
government,16 and consequently hospital systems often push providers 
to meet standardized performance measures to comply with 
requirements outlined by the federal government.17  While this 
procedure was implemented in an effort to improve quality, instead it 
placed unnecessary and distracting requirements on the patient visit – 
frustrating both the patient and the provider.  For example, 2019 marks 
“year three” of Medicare MIPS reimbursement model.18  Under this 
program, providers receive an allocated deduction of 7% in Medicare 
reimbursement costs for failing to satisfy quality reporting measures.19  
While this program in theory promotes quality of care, because these 
guidelines are generalized, a Medicare patient being seen for a specific 
issue may be required to answer seemingly irrelevant questions about 
their general health in an effort for the provider to meet the MIPS 
measure.20  In essence, these Medicare reimbursement guidelines are 
complex, confusing, and often force providers to focus on ways to meet 
                                                          
16. Tamera Jackson, Medicare Reimbursement, MEDICARE.COM (July 6, 2018), 
https://medicare.com/administration/how-do-i-get-reimbursed-by-medicare. 
17. Congress has served as a catalyst for this trend in its efforts to convert 
Medicare reimbursement rates to a merit-based system.  Alas, “CMS is required by 
law to implement quality payment incentive program[s],” including the Merit-based 
Incentive Payment System (MIPS) to meet those requests, replacing previous 
programs like PQRS.  Under MIPS, eligible-clinicians (determined by clinician type, 
volume of charges under the Medicare Physician Fee Schedule, and the number of 
Medicare Part B patients) are rewarded based on value and patient outcomes.  Each 
clinician’s performance measure is determined on scores in quality, improvement 
activities, promoting interoperability, and cost.  Each category is based on specific 
measures created by CMS.  Performance in these categories are converted into a score, 
which determines each clinician’s payment adjustment for their Medicare patients.  
Thus, clinicians are required to meet these measures to “earn” the greatest 
reimbursement.  MIPS Overview, DEP’T OF HEALTH & HUMAN SERVICES, https://qpp. 
cms.gov/mips/overview (last visited May 1, 2019).  
18. Susan Moschella, 2019 MIPS Requirements, MEDISOLV: BLOG (Nov. 16, 
2018), https://blog.medisolv.com/2019-mips-requirements. 
19. Id.  “Each category of MIPS has a different set of requirements that you 
must follow in order to fully participate and have your best chance at earning incentive 
money. There are four categories that make up the MIPS program: quality, promoting 
interoperability (formerly advancing care information), improvement activity, and 
cost. Each of these categories carries a different weight. Your score in each category 
will be totaled into one final MIPS score.”  Id. 
20. 2019 MIPS Rules, MD INTERACTIVE, https://mdinteractive.com/2019-mips-
rules (last visited May 1, 2019).  
6
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a reimbursement measure rather than a patient’s chief complaint.  
Moreover, given its profitability, current and conventional healthcare 
policy focuses on “cost versus quality.”21 
Americans spend 60% more on insurance than citizens of any other 
developed country in the world and typically receive health insurance 
through their employer, the government, or a private payer system.22  
Those who are unable to afford private coverage, do not receive benefits 
from their employer, and are not eligible for Medicare,23 may be 
eligible for Medicaid;24 but many have no coverage at all.25  This 
system functions as an incomplete patchwork of coverage, leaving 
many Americans unable to afford insurance premium costs.26  
Consequently, the healthcare industry covers the costs for those who 
choose, or are financially obliged not to have health insurance.27 
Furthermore, healthcare costs are greatly influenced by the United 
States pharmaceutical market,28 which totals over $1 trillion a year.29  
The United States has a unique approach to pharmaceuticals as its drug 
regulations do not extend beyond safety and efficacy.  Therefore, once 
approved under the safety standards set forth by the Food and Drug 
                                                          
21. Nicolas P. Terry, Will the Internet of Things Transform Healthcare?, 2 
VAND. J. ENT. & TECH. L. 327, 329 (2016). 
22. Daemmrich, supra note 14, at 2. 
23. See 42 U.S.C. § 1395c (2019). 
24. See 42 U.S.C. § 1396a(a)(10) (2018). 
25. Guixiang Zhao et al., Trends of Lack of Health Insurance Among US Adults 
Aged 18-64 Years: Findings from the Behavioral Risk Factor Surveillance System, 
1993-2014, 146 PUB. HEALTH 108, 109 (2017). 
26. Notably, 60% of bankruptcies in 2007 stemmed from medical debts. 
Daemmrich, supra note 14, at 2 (citing David Himmelstein et al., Medical Bankruptcy 
in the United States, 2007: Results of a National Survey, 122 AM. J. MED. 74 (2009)).  
27. Maureen Groppe, Who Pays When Someone Without Insurance Shows Up 
in the ER?, USA TODAY (July 13, 2017, 1:14 AM), https://www.usatoday.com/story 
/news/politics/2017/07/03/who-pays-when-someone-without-insurance-shows-up-
er/445756001. 
28. The United States holds over 45% of the global pharmaceutical market. U.S. 
Pharmaceutical Industry – Statistics & Facts, STATISTA, https://www.statista.com/to 
pics/1719/pharmaceutical-industry (last visited May 1, 2019). 
29. In 2015, the economic output from the pharmaceutical industry included 
$558 billion in revenue for biopharmaceutical businesses and $659 billion from 
suppliers and worker spending. Biopharmaceutical Spotlight: The Biopharmaceutical 
Industry in the United States, SELECT USA, https://www.selectusa.gov/pharmaceu 
tical-and-biotech-industries-united-states (last visited May 1, 2019). 
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Administration (FDA), the government does not regulate or negotiate 
prescription drug prices.30  Many other countries task government 
agencies with determining prescription pricing.31  Instead, the United 
States allows drug makers to set their own prices for a given 
prescription.32  As a result, each of the thousands of health insurance 
plans, including Medicare, negotiates its own prices with drug makers 
separately.33 
Unfortunately for the American consumer, the fragmented 
dispersal of health insurance plans has diminished insurers’ bargaining 
power to demand lower prescription costs for their policy holders.34  
Consequently, the cost of a given medication differs drastically in the 
United States compared to the cost of the same medication in any other 
country in the world.35 
B. Technology and Healthcare 
In light of growing demand, the healthcare industry has shifted its 
willingness to incorporate technology into the traditional delivery 
model.  Industry professionals believe incorporating technology will 
improve quality of care and accessibility of healthcare services.  
Beyond technological advances in care specifically, hospital systems 
have been encouraged to embrace technology since the early 2000s.  At 
that time, lawmakers hoped to incentivize hospital systems to transition 
from paper to electronic charting by including the Privacy Rule in an 
effort to improve documentation and patient care.36 
                                                          
30. Sarah Kliff, The True Story of America’s Sky-High Prescription Drug 
Prices, VOX (May 10, 2018, 9:19 AM), https://www.vox.com/science-and-health/ 
2016/11/30/12945756/prescription-drug-prices-explained. 
31. Id. 
32. Id. 
33. Nearly every drug approved by the FDA is covered by Medicare because 
Federal law expressly prohibits negotiating drug prices or making decisions about 
which drugs it covers.  Id. 
34. Id. 
35. For example, in 2015, the prescription medication “Humira” (used to treat 
arthritis and psoriasis) cost approximately $1,362 in the United Kingdom, $822 in 
Switzerland, and $2,669 in the United States.  Id. 
36. Recognizing a need to “maintain strict privacy protection for health 
information,” Congress authorized the Privacy Rule which “creates national standards 
to keep individuals’ medical records and other personal health information 
8
California Western Law Review, Vol. 55 [2019], No. 2, Art. 9
https://scholarlycommons.law.cwsl.edu/cwlr/vol55/iss2/9
Mollie Levy camera ready FINAL (Do Not Delete) 7/10/2019  9:10 AM 
2019] MARKETING MEDICINE TO MILLENNIALS 529 
More recently, technology is making its way into the physician-
patient encounter.  First introduced by NASA in the 1960s to provide 
treatment to astronauts,37 today telemedicine – utilizing audio and video 
equipment to establish “two-way, real time interactive communication 
between the patient, and the physician or practitioner at a distant site”38 
– provides a cost-effective alternative to the traditional face-to-face 
healthcare delivery model by servicing remote or underserved 
communities.39  While telemedicine is not new, federal and state 
legislatures have failed to recognize its benefits on expanding access, 
decreasing cost, and improving quality of care until recently.40  For 
example, not until 2018 did Congress pass a law to authorize  
reimbursement for care provided via telemedicine to rural 
populations.41 
However, nearly a decade earlier Congress began allowing online 
pharmacies to exist and operate freely.42  Unlike the tight regulations 
restricting traditional healthcare delivery, online pharmacies are merely 
required to satisfy state regulations.43  Given the majority of online 
pharmacies are based outside of the United States, these companies 
have circumvented regulation.44  Consequently, the illegal prescription 
                                                          
confidential” by restricting health care providers from releasing patient medical 
records and guaranteeing patient access to their medical records. 45 C.F.R. §§ 160, 
164.524(b)(2) (2013). 
37. Vera Gruessner, The History of Remote Monitoring, Telemedicine 
Technology, MHEALTH INTELLIGENCE (Nov. 9, 2015), https://mhealthintelligence. 
com/news/the-history-of-remote-monitoring-telemedicine-technology. 
38. Telemedicine, MEDICAID.GOV, https://www.medicaid.gov/medicaid/bene 
fits/telemed/index.html (last visited May 1, 2019).  
39. Ioana Ciopraga, The FDA Guidance Document of Medical Mobile Apps and 
its Impact on Innovation: Bringing the Promise of a New Way to Look at Medicine 
Closer, or Pushing it Further, 6 J.L. TECH. & INTERNET 43, 45-46 (2015). 
40. Telemedicine Benefits, AM. TELEMEDICINE ASS’N., http://www.american 
telemed.org/main/about/about-telemedicine/telemedicine-benefits (last visited May 
1, 2019). 
41. 38 U.S.C. § 1730C (2018); see also id. 
42. 21 U.S.C. § 831 (2009). 
43. Ross D. Silverman, Regulating Medical Practice in the Cyber Age: Issues 
and Challenges for State Medical Boards, 26 AM. J. L. & MED. 255, 267 (2000).   
44. A random sample of 10,000 online pharmacies by the FDA found that 97% 
of them were either illegal or out of compliance with regulations. Illegal Online 
Pharmacies: How Endemic Are They?, PHARMACEUTICAL TECH. (July 20, 2018), 
9
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drug market has blossomed over the last decade, and there are 
approximately 40,000 illegal online pharmacies today.45 
The online pharmaceutical market also incentivizes patients to 
avoid the traditional healthcare model, as patients seek faster treatment 
by skipping the face-to-face provider visit and locating a desired 
medication online.46  In effect, online prescribing represents another 
way in which the internet offers “unparalleled opportunities for 
individuals to get exactly what they want.”47  It is no surprise that one 
in four American consumers purchases their prescription medications 
online.48 Thus, the healthcare industry has made attempts to incorporate 
technology into its traditional delivery model, but is limited by the 
limited pace of legislation  and political priorities.  The difference in 
Congress’ treatment of telemedicine and online pharmacies shows that 
inconsistencies in regulation that leave the markets for healthcare 
delivery open to abuse lead to direct, negative impacts on consumers. 
C. The Shift in Healthcare Delivery 
Without question—tech companies are betting on healthcare.49  
Within the last five years, the top ten tech companies in the United 
States have spent over $4.5 billion to finance healthcare projects.50  
Since the introduction of eCommerce, companies like Amazon have run 
out competitors in numerous markets by offering direct-to-consumer 
products at minimal cost, time, or risk to the consumer.51  Healthcare 
                                                          
https://www.pharmaceutical-technology.com/comment/illegal-online-pharmacies-
endemic [hereinafter Illegal Online Pharmacies]. 
45. Id. 
46. Silverman, supra note 43, at 266. 
47. Id. 
48. Illegal Online Pharmacies, supra note 44. 
49. See Where Big Tech is Placing Bets in Healthcare, CB INSIGHTS (Sept. 13, 
2018), https://www.cbinsights.com/research/top-tech-companies-healthcare-investm 
ents-acquisitions [hereinafter Tech Bets]; see generally Pearl, supra note 1.  
50. Id.  
51. Experts believe Amazon is currently threatening healthcare, electronic 
retailers, consumable manufacturers, department stores, high-end department stores, 
food delivery, bookstores, grocery stores, package delivery and logistics.  Kate 
Taylor, Mary Hanbury, & Dennis Green, Amazon’s Growth Could Threaten These 10 
Industries, BUS. INSIDER (June 28, 2018, 12:11 PM), https://www.businessinsider. 
com/amazon-is-killing-these-7-companies-2017-7#pharmacy-9. 
10
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has become Amazon’s most recent target, and in a recent acquisition 
the company purchased an eCommerce prescription medication 
platform called PillPack for close to $1 billion.52 
This buy-in is indicative of a pattern of market shifts we have seen 
in other sectors.  In the 1980s, mega retailers like K-Mart, Sears, and 
Target were the typical outlet for average consumers to shop for 
household items; today, all but one has filed for bankruptcy.53  This is 
largely due to eCommerce’s ability to consolidate markets because of 
its superior convenience and cost-effectiveness.  Amazon’s investment 
in pharmaceutical eCommerce is a strong sign that swaths of the 
healthcare industry may fall in the same way.  Thus, a change in 
healthcare delivery is undoubtedly inevitable.  As such, without 
legislative reform allowing direct-to-consumer products in the industry, 
the traditional healthcare delivery model may meet a similar fate as that 
of Blockbuster54 and Borders Books.55 
With the recent generation shift, Millennials have become the 
largest segment of the American consumer market.56  However, 
                                                          
52. Ingrid Lunden, Amazon Buys PillPack, an Online Pharmacy, for Just Under 
$1B, TECH CRUNCH (June 2018), https://techcrunch.com/2018/06/28/amazon-buys-
pillpack-an-online-pharmacy-that-was-rumored-to-be-talking-to-walmart. 
53. See Chris Isidore, Sears’ Extraordinary History: A Timeline, CNN (Oct. 15, 
2018), https://www.cnn.com/interactive/2018/10/business/sears-timeline/index.html; 
Jeanette L. Nolen, Target Corporation: American Corporation, ENCYCLOPEDIA 
BRITANNICA (Mar. 14, 2019), https://www.britannica.com/topic/Target-Corporation; 
A Timeline of the Kmart Corporation, N.Y. TIMES (Jan. 22, 2002), https://www.nyt 
imes.com/2002/01/22/business/a-timeline-of-the-kmart-corporation.html. 
54. Blockbuster went bankrupt in 2000 after refusing to accept a partnership 
offer from Netflix, an online media streaming company which is now the world’s most 
highly valued media and entertainment company. Greg Satell, A Look at Why 
Blockbuster Really Failed and Why it Didn’t Have to, FORBES (Sept. 5, 2014), 
https://www.forbes.com/sites/gregsatell/2014/09/05/a-look-back-at-why-blockbuster 
-really-failed-and-why-it-didnt-have-to/#21934d011d64. 
55. Borders Books went bankrupt in 2011 after outsourcing its online book sales 
to Amazon instead of developing a competitive e-reader device or offering sales 
online. Josh Sanburn, 5 Reasons Boarders Went Out of Business (and What Will Take 
its Place), TIME (July 19, 2011), http://business.time.com/2011/07/19/5-reasons-
borders-went-out-of-business-and-what-will-take-its-place. Amazon is now the 
world’s largest eCommerce supplier, valued at $1 trillion.  Joel Anderson, How Much 
is Amazon Worth?, GO BANKING RATES (July 26, 2018), https://www.gobanking 
rates.com/making-money/business/how-much-is-amazon-worth. 
56. According to a census taken on July 1, 2017, Millennials account for over 
23% of the United States population.  How Many Millennials, supra note 3. 
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Millennials are the least likely to utilize the traditional healthcare 
delivery model.  Survey data indicates that many Millennials do not see 
a doctor regularly.57  Millennials seem to share the opinion that the 
time-honored model of regular office-based primary care is fading, and 
models that offer greater convenience, fast service, connectivity, and 
price transparency are preferable.58 
Millennials serve a pivotal role in the success of the healthcare 
industry.  Without Millennials buying in to the pillared insurance 
scheme while healthy, there is less money to cover the costs of older 
generations.59  That cost spreading is required to balance the high costs 
of delivering healthcare to aging and illness-prone populations.60  
Furthermore, without Millennials utilizing preventative medicinal 
strategies, their risk of disease increases; it is uncertain whether the 
industry will be able to support them when they do eventually require 
focused care.61  Simply put, the traditional model no longer fits the 
desires of the average consumer, and the projected needs of the 
healthcare market. 
Given the huge financial incentive for online retailers to continue 
consolidating an unfettered direct-to-consumer market, and the 
                                                          
57. A 2015 survey indicated that 9 out of 10 millennials do not see a doctor 
regularly, and 51% of millennials see a doctor less than once a year. Amy Juaristi, 
New Study: Why Americans are Dropping Out of Healthcare, ZOCDOC (June 23, 
2015), https://www.zocdoc.com/about/news/new-study-why-americans-are-dropping 
-out-of-healthcare. 
58. One millennial compared the convenience of urgent care to that of “speed 
dating” where the “services are rendered in a quick manner.” Sandra G. Boodman, 
For Millennials, a Regular Visit to the Doctor’s Office is not a Primary Concern, 
WASH. POST (Oct. 6, 2018), https://www.washingtonpost.com/national/health-scien 
ce/for-millennials-a-regular-visit-to-the-doctors-office-is-not-a-primary-concern/201 
8/10/05/6b17c71a-aef3-11e8-9a6a-565d92a3585d_story.html?utm_term=.fbffa34fab 
71. 
59. Notably, before the ACA, young adults had the highest uninsured rate of 
any age group. Carmen Heredia Rodriguez, This is Why Millennials are Struggling to 
Get Health Insurance, TIME (Dec. 6, 2017), http://time.com/5052313/health-insur 
ance-obamacare-challenges. 
60. COMM. ON THE CONSEQUENCES OF UNINSURANCE, INST. OF MED., HIDDEN 
COSTS, VALUES LOST: UNINSURANCE IN AMERICA 38, 56 (US) (2003).  Multi-
generational cost spreading also aids in absorbing the cost of health care services 
received by uninsured individuals which otherwise is covered by practitioners, 
institutions, and the federal government.  Id. at 60–61.  
61. Boodman, supra note 58.   
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generational shift towards demand for such a model, the writing is on 
the wall for traditional modes of healthcare delivery.  While advertising 
and marketing trends within other industries have adjusted in an effort 
to capitalize on comparable shifts, the traditional healthcare model has 
not.  The concern being that an eCommerce or direct-to-consumer 
healthcare delivery model is one which the traditional healthcare 
industry will be unable to incorporate without adjustments to the 
government’s current tight regulatory control.  As discussed below, 
emerging direct-to-consumer health products are unaddressed by 
current legislation.  These products have the potential to expand care, 
decrease costs, and capture the Millennial market.  If the traditional 
healthcare delivery model fails to incorporate direct-to-consumer 
alternatives, the existence of the healthcare industry may be jeopardized 
as the market shifts away from the traditional delivery model. 
II. DIRECT-TO-CONSUMER MEDICINE 
The healthcare industry has long opposed direct-to-consumer 
advertising strategies, arguing they misinform patients, cripple 
providers’ abilities to provide adequate care, lead to inappropriate 
prescribing, and escalate drug costs.62  Astonishingly, nearly 800,000 
pharmaceutical advertisements air on television in a given year.63  
Considering the average American watches sixteen hours of 
pharmaceutical television advertisements a year, the traditional 
healthcare industry’s concerns are warranted.64 
While these ads have become common place, they were highly 
controversial when first introduced in the 1980s.65  At that time, 
pharmaceutical companies mimicked the model used in other industries 
                                                          
62. Natasha Parekh & William H. Shrank, Dangers and Opportunities of Direct-
to-Consumer Advertising, 33 J. GEN. INTERNAL MED. 586, 586 (2018)  (citing C. 
Lee Ventola, Direct-to-Consumer Pharmaceutical Advertising Therapeutic or 
Toxic?, 36 PHARMACY & THERAPEUTICS 669, 669-74 (2011), and Kurt C. Stange, 
Time to Ban Direct-to-Consumer Prescription Drug Marketing, 5 ANNALS FAM. 
MED. 101, 101-04 (2007)). 
63. Joanne Kaufman, Think You’re Seeing More Drug Ads on TV? You Are, and 
Here’s Why, N.Y. TIMES (Dec. 24, 2017), https://www.nytimes.com/2017/12/24 
/business/media/prescription-drugs-advertising-tv.html. 
64. Parekh & Shrank, supra note 62, at 586.  
65. The first direct-to-consumer pharmaceutical advertisement was for the 
Pneumovax vaccine in 1981.  Id. 
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by marketing medications directly to the American consumer.  This 
marketing strategy encouraged patients to request specific drug 
treatment from their providers, thus abrogating providers’ discretion to 
recommend appropriate medications.  The strategy was 
overwhelmingly successful.66 
A. Direct-to-Consumer Advertising in Healthcare 
The United States is one of only two countries in the world that 
permits direct-to-consumer marketing within the healthcare industry.67  
Despite growing outrage among medical providers, the FDA has been 
very slow to respond to concerns raised about direct-to-consumer 
marketing schemes.  In the 1960s, Congress granted the FDA 
prescription drug labeling and advertising regulation authority in an 
effort to ensure ads were not misleading consumers.68  However, after 
direct-to-consumer advertising exploded in the 1990s, the FDA eased 
previously enforced “risk” requirements.69  Instead, the FDA merely 
required direct-to-consumer pharmaceutical advertisements to include 
the “major risks” associated with each medication.70  Consequently, the 
number of direct-to-consumer pharmaceutical advertisements 
skyrocketed.71 
In response to continuous and systematic misrepresentation of 
pharmaceutical drugs in the market, the FDA implemented new 
                                                          
66. “The average television viewer in the United States . . . watches as many as 
nine drug advertisements per day and about 16 hours per year, far exceeding the time 
an average individual spends with his/her primary physician.”  Id.  
67. New Zealand is the other country that permits direct-to-consumer drug 
advertising; Canada also allows ads that mention the product or the indication of a 
drug, but the ad cannot include both.  Ventola, supra note 62, at 669. 
68. This authority included ensuring that ads presented a “fair balance” of both 
drug risks and benefits, included facts that are “material” to a drug’s advertised uses, 
and included a “brief summary” that notes every risk described in the drug’s labeling. 
Parekh & Shrank, supra note 62, at 586. 
69. Id. 
70. Id. 
71. Today, pharmaceutical companies spend $5 billion on drug commercials a 
year.  Id. 
14
California Western Law Review, Vol. 55 [2019], No. 2, Art. 9
https://scholarlycommons.law.cwsl.edu/cwlr/vol55/iss2/9
Mollie Levy camera ready FINAL (Do Not Delete) 7/10/2019  9:10 AM 
2019] MARKETING MEDICINE TO MILLENNIALS 535 
guidelines in 2012.72  The main effect of these guidelines is that 
advertisers now simply add a laundry-list of side effects to the tail-end 
of advertisements.  Many researchers suggest these guidelines continue 
to fail the American consumer, as the “benefit vs risk” requirement73 
remains inadequate.74  Thus, consumers continue to be misled.  
Furthermore, these warnings have become so common place they are 
often overlooked by the average consumer. 
Recently, the FDA has been receiving more applications for direct-
to-consumer advertisements as medical device companies are 
employing similar strategies.75  Unfortunately, the FDA struggles to 
update regulations, and direct-to-consumer advertising strategies 
undermine regulatory restrictions by encouraging more medical 
products to be used at home. 
B. Direct-to-Consumer Health Products 
The demands of Millennial consumers have forced a 
reconceptualization of how goods are marketed and sold.  Unlike 
preceding generations, Millennials quickly adopted purchasing habits 
that eliminate the need of an in-person retailer.  As Millennial 
consumers shifted their spending to e-Commerce, other services 
developed direct-to-consumer options to capitalize on the change.  
Specifically, tech companies have captured the Millennial consumer 
with direct-to-consumer health products, a mode of delivery the 
traditional healthcare industry has not been able to adopt. 
                                                          
72. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY DIRECT-TO-
CONSUMER TELEVISION ADVERTISEMENTS – FDA DTC TELEVISION AD PRE-
DISSEMINATION REVIEW PROGRAM (Draft Guidance 2012). 
73. “Benefit versus risk” is the minimum requirement a product must satisfy to 
obtain FDA approval; the standard is that the product’s benefits must outweigh its 
risks.  Parekh & Shrank, supra note 62, at 587. 
74. Id. at 586–87. 
75. “As the regulating body of DTC advertising, the FDA is responsible for 
ensuring that advertising ‘is truthful, balanced, and accurately communicated’ 
through regulation, surveillance, and education.”  Id. (quoting The Impact of Direct-
to-Consumer Advertising, U.S. FOOD & DRUG ADMIN. (2015), https://www.fda. 
gov/Drugs/ResourcesForYou/Consumers/ucm143562.htm). 
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1. Medical Devices 
Within the last ten years, biotechnology companies have 
capitalized on the trend toward direct-to-consumer advertising by 
focusing on medical devices for use at home.  The FDA defines medical 
devices as instruments “intended for use in the diagnosis of disease or 
other conditions, . . . the cure, mitigation, treatment, or prevention of 
disease, or . . . to affect the structure of any function of the body of man 
or other animals.”76  Unfortunately, the FDA’s conception of a medical 
device fails to encompass all products available on the market for 
purchase, and fails to link the medical device to the healthcare provider.  
Effectively, these direct-to-consumer medical devices can create larger 
gaps in care as providers are unaware of any decisions the patient may 
have made based off direct-to-consumer products.77 
The rise of wearable fitness trackers is a notable example of this 
phenomenon.  What started as a tool to support healthy lifestyles, 
evolved into a device that not only encourages but also drives care.  
When introducing the newest Apple Watch model in 2018, Apple COO 
Jeff Williams announced the watch’s sensor technology promises to 
“become an intelligent guardian for your health.”78  Effectively, Apple 
has promised its consumers they now have the ability to monitor their 
own health by means such as tracking their heart rhythm so 
abnormalities can be detected by simply wearing the watch.79  Features 
like these may allow consumers to make better decisions about their 
health, but they are also indicative of big tech’s leverage on the market 
                                                          
76. Jamie Lynn Flaherty, Digital Diagnosis: Privacy and the Regulation of 
Mobile Phone Health Applications, 40 AM. J. L. & MED. 416, 422 (2015). 
77. Providers make medical recommendations based on a review of the detailed 
patient record, evaluation of current symptoms, and a physical examination. Critical 
data captured in a direct-to-consumer product is undoubtedly missing from the 
patient’s medical record.  
78. On September 12, 2018, while introducing the newest model of Apple 
Watch Series 4, Apple COO Jeff Williams announced the Watch’s “health sensor.” 
Sara Salinas & Eugene Kim, Apple Adds Heart Monitoring to Apple Watch, CNBC 
(Sept. 12, 2018, 1:13 PM), https://www.cnbc.com/2018/09/12/apple-watch-series-
4.html. 
79. Id. 
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for novel healthcare solutions.80  As economists note: “Apple just gave 
every Android user a life-saving reason to switch to the iPhone.”81 
Similar to the health monitoring services emerging from big tech, 
other novel health services are becoming widespread and influential.  
Nearly a decade ago, a biochemist in Silicon Valley developed the first 
at home genetic testing kit that could provide health reports based on 
DNA samples collected from customers’ saliva.82  After launching in 
2009, 23andMe prospered until the FDA ordered the company cease all 
sales in 2013 for providing medical information directly to its 
consumers from an unregulated medical device.83  Unlike its 
competitors, who focused efforts on ancestry, 23andMe advertised its 
ability to provide health information while never undergoing FDA 
certification.84  Today, despite its marketing insisting information about 
genetic health risks, wellness, and carrier status,85 23andMe is only 
approved to notify consumers of the risks of developing ten medical 
conditions based on their DNA.86 
At home genetic testing and wearables present new problems to the 
FDA; both products effectively market themselves as medical devices, 
yet are shielded from regulation by the loose language of the FDA’s 
definition.  Furthermore, with big tech’s continued investments in the 
                                                          
80. It was predicted that Apple would ship 18 million units in 2018. Mikey 
Campbell, Kuo: High PreOrder Demand for Apple Watch Series 4, Low Expectations 
for 5.8 Inch iPhone XS, APPLE INSIDER (Sept. 16, 2018, 8:53 PM), https://appleinsider 
.com/articles/18/09/16/kuo-high-preorder-demand-for-apple-watch-series-4-low-exp 
ectations-for-58-inch-iphone-xs. 
81. Salinas & Kim, supra note 78.  
82. In 2006, Anne Wojcicki sought to disrupt the healthcare industry and put 
“sophisticated DNA analyses into the hands of . . . consumers, giving them 
information about health, disease, and ancestry.”  Erika C. Hayden, The Rise and Rise 
Again of 23andMe, NATURE (Oct. 11, 2017), https://www.nature.com/news/the-rise-
and-fall-and-rise-again-of-23andme-1.22801.  
83. Id. 
84. See David Dobbs, The F.D.A. vs. Personal Genetic Testing, THE NEW 
YORKER (Nov. 27, 2013), https://www.newyorker.com/tech/annals-of-technology/ 
the-f-d-a-vs-personal-genetic-testing (observing that 23andMe operated without FDA 
approval). 
85. Our Health + Ancestry DNA Service, 23ANDME, https://www.23andme. 
com/dna-health-ancestry (last visited May 1, 2019).  
86. In 2017, the FDA approved notifying consumers of the risks of developing 
ten specific medical conditions based on their DNA, including Parkinson’s disease 
and late-onset Alzheimer’s.  Hayden, supra note 82. 
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industry, it is likely additional products are already in development that 
are essentially medical devices, but will reach consumers without being 
regulated by the FDA. 
2. The mHealth Boom 
Over the last five years, the prevalence of mobile health 
applications (“mHealth apps”) have exploded.  From 2015 to 2017, the 
number of mHealth apps available for download doubled,87 and the 
market for these apps is estimated to be $26 billion.88  The FDA 
estimates that over 500 million smartphone users have downloaded at 
least one mHealth app.89  Experts anticipate this boom will continue as 
the mobile app economy90 is expected to increase in size from $1.3 
trillion to $6.3 trillion by 2022.91 
Unlike other direct-to-consumer products, mHealth apps allow for 
unlimited access to care without significant effort by the consumer.  
However, unbeknownst to the public, these mHealth apps are widely 
unregulated because even apps that are considered “medical devices” 
escape regulation if they are not classified as a “high risk.”92  
Regulation of mHealth apps is especially complex because it involves 
four separate governmental agencies, each focusing on distinct aspects 
within the application, and fails to assess the application in its entirety.93 
                                                          
87. Terry, supra note 21, at 333.   
88. Michelle M. Ovansian, Healthcare Begins a Mobile Revolution, 1 GEO. L. 
TECH. REV. 170, 170 (2016). 
89. Id. at 173. 
90. App Economy includes buying and downloading applications, making 
purchases within the applications, and targeted advertising within those applications. 
Gene Marks, The App Economy is About to Explode, WASH. POST (June 28, 2017), 
https://www.washingtonpost.com/news/on-small-business/wp/2017/06/28/the-app-
economy-is-about-to-explode/?noredirect=on&utm_term=.c48770d0a8eb. 
91. Id.  Economists suspect mobile shopping could be the reason behind this 
expected increase, as “the mobile commerce market now accounts for approximately 
90 percent of mobile app usage[.]”  Id. 
92. Under current law, the FDA regulates only those apps that qualify as 
“medical devices and/or pose significant risks to patients” and most mHealth apps fall 
outside of that category.  Flaherty, supra note 76, at 418–22.  
93. Current regulators of mHealth include The Health and Human Services 
Office of Civil Rights, the Federal Trade Commission, the Federal Consumer 
Commission, and the Food and Drug Administration. Recently, all four government 
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As an example, the healthcare data collected by mHealth apps 
creates an unanticipated wrinkle for the FTC, tasked with protecting 
sensitive health information that is owned by individual 
telecommunication carriers.  Most mobile applications regulated by the 
FTC are not required to comply with HIPAA’s zone of protection,94 
thus the FTC’s regulation of data is not extensive enough to protect 
patient information stored in mobile data.95,96  Moreover, mHealth apps 
face unique cyber security concerns, as the FTC has not completely 
reigned in the use of consumer data, and not all suppliers even require 
privacy disclosures.97 
The complexities of this emerging health technology as it relates to 
FTC regulation alone illuminate the shortfalls already present in 
regulation.  This is so even without considering the difficulties created 
by mHealth apps for the FCC, FDA, and Health and Human Services 
Office of Civil Rights, and the oncoming wave of such technologies 
that the current market shift promises. 
3. Pharmaceuticals 
The pharmaceutical industry is moving into the direct-to-consumer 
realm as well, and major online retailers are tackling the traditional 
pharmaceutical market head on.98  In June 2018, Amazon acquired a 
                                                          
organizations “jointly developed an interactive tool in an attempt to guide application, 
or app developers through the regulatory confusion.”  Terry, supra note 21, at 339. 
94. HIPAA, a statutory protection of privacy in health information, contains a 
“zone of protection” which requires healthcare institutions to protect the disclosure of 
patient health information. Mobile apps are not within this zone because HIPAA 
attaches to the individual housing the data and not the data itself.  Thus, since mHealth 
apps are not developed or operated by a healthcare institution as defined by the law, 
they are not held to guidelines required by HIPAA.  Id. 
95. The FDA has divided the types of mobile apps subject to oversight into three 
distinct categories: (1) those that are extensions of medical devices; (2) those that 
transform a mobile platform into a medical device; and (3) those that become a 
regulated medical device.  Ciopraga, supra note 39, at 49. 
96. Flaherty, supra note 76, at 422. 
97. This article will not discuss the litany of cyber security issues associated 
with mHealth apps. 
98. See Angelica LaVito, Amazon has Quietly Launched an Exclusive Line of 
Over-the-Counter Health Products, CNBC (Feb. 20, 2018, 3:14 PM), https://www.cn 
bc.com/2018/02/20/amazon-has-quietly-launched-an-exclusive-line-of-over-the-cou 
nter-health-products.html. 
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supplier of customized medication packs called PillPack for just under 
$1 billion according to sources close to the deal.99  PillPack offers 
delivery of all prescription medications, vitamins, and any over-the-
counter medications in individual daily packs for the consumer.100  This 
service makes accessing, dividing, and taking medications from 
multiple medical providers easier.101  To facilitate this process, PillPack 
developed software that accounts for multiple prescriptions taken at 
once.102  This approach to prescription delivery removes the complexity 
and frustration of managing multiple medications while establishing a 
radical shift in chronic care management.103 
Amazon’s willingness to pay ten figures for a service like PillPack 
is indicative of its potential to reshape the traditional pharmaceutical 
model.104  However, the traditional pharmacy model would never be 
able to sustain such an effective service as it stands today because 
traditional pharmacies do not have the infrastructure to achieve this end.  
The loose regulation of online pharmacies discussed above, coupled 
with big technology companies’ economic clout, thus threaten to force 
ill-equipped and overregulated traditional models to fall by the wayside. 
C. Current Regulations 
In the last two decades, the United States government has focused 
intently on issues related to healthcare because of their effect on so 
many people.  In the late 1990s, Congress addressed protections for 
patients in the clinical setting with the passage of the Health Insurance 
                                                          
99. Lunden, supra note 52. 
100. How it Works, PILLPACK, https://www.pillpack.com/how-it-works (last 
visited May 1, 2019). 
101. Id.  
102. PhamarcyOS constantly monitor’s your prescriptions, making required 
changes when necessary, takes a comprehensive view of client’s medications, 
synchronizes medications, and tracking any anticipated changes in medications. The 
Pharmacy System that Goes Beyond the Pharmacy, PILLPACK: PHARMACYOS, 
https://www.pharmacyos.com (last visited May 1, 2019).  
103. Id.  
104. Prior to Amazon’s announcement, the “global online pharmacy market was 
worth about $29 billion,” and predicted to reach $128 billion by 2023.  Jim Butschili, 
Amazon’s PillPack Acquisition Could Transform Online Pharmacy Market, 
LOGISTICS FOR THE LIFE SCI. (July 16, 2018), https://www.logisticsforthelifesci 
ences.com/amazons-pillpack-acquisition-could-transform-online-pharmacy-market.  
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Portability and Accountability Act of 1996 (HIPAA).105  HIPAA was 
intended to improve the continuity of health insurance coverage, 
decrease fraud, improve access to long-term care, address privacy 
concerns, and simplify the administration of health insurance.106  More 
recently, Congress passed broad legislation to address the financial 
impact of healthcare on patients with the Patient Protection and 
Affordable Care Act.107  While such legislation is put in place to protect 
patients, it has greatly limited the ability of traditional institutions in the 
industry to enter the direct-to-consumer market. 
When passing HIPAA, Congress specifically targeted Medicare 
fraud in an effort to protect the patient.108  However, when it comes to 
other healthcare legislation, it appears Congress was willing to overlook 
possible industry-wide abuse – including Medicare fraud and substance 
abuse – by allowing online pharmacies to exist with limited 
restriction.109  Perhaps persuaded by the economic impact of the 
pharmaceutical industry, recent legislation suggests public policy 
supports less restrictions on the sale of specific medicinal commodities 
compared to the service of providing care. 
                                                          
105. See generally Health Insurance Portability and Accountability Act, Pub. L. 
No. 104–191, 100 Stat. 2548 (1996) [hereinafter HIPAA]. 
106. “HIPAA represents a large and very significant legislative reform of the 
health insurance industry, and is codified primarily in Titles 18, 29, and 42 of the 
United States Code.”  Deborah F. Buckman, Validity, Construction, and Application 
of Health Insurance Portability and Accountability Act of 1996 (HIPAA) and 
Regulations Promulgated Thereunder, 194 AM. L. REP. FED. 133 (2004).  See also 
Clay J. Countryman, HIPAA and the Practice of Law, 52 LA. B.J. 103, 103 (2004). 
107. See generally Patient Protection and Affordable Care Act, 111 Pub. L. 148, 
124 Stat. 119 (2010). 
108. See Buckman, supra note 106.  
109. A specific example of lack of oversight is the opioid epidemic. In 2017, 
Health and Human Services declared the United States opioid epidemic a public 
health emergency after over 47,000 Americans died from opioid overdoses in a single 
year. What is the U.S. Opioid Epidemic?, U.S. DEPT. HEALTH & HUM. SERVICES, 
https://www.hhs.gov/opioids/about-the-epidemic/index.html (last visited May 1, 
2019).  Significantly, “[t]he Centers for Disease Control and Prevention estimates that 
the total ‘economic burden’ of prescription opioid misuse alone in the United States 
is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction 
treatment, and criminal justice involvement.”  Opioid Overdoes Crisis, NAT’L INST. 
DRUG ABUSE, https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-
crisis (last visited May 1, 2019). 
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Unlike the direct-to-consumer model, there are several realities that 
make the traditional model uncompetitive including complicated cost 
structures, time inefficiencies, and geographic challenges.  The 
economics of healthcare are complicated as, unlike other industries, 
healthcare delivery relies primarily on insurance reimbursement to 
drive cost.  Under this model, healthcare providers rely on guidelines 
set out by insurance companies to navigate appropriate treatment 
options, which limits innovation and consumer choice.  Furthermore, 
the traditional model has been around for a century, and its entrenched 
structure makes acquiring healthcare services a significant time 
commitment for patients.110  The current model involves patient time 
spent receiving, reviewing, and reconsidering treatment plans, and 
receiving proper care often takes multiple visits with multiple 
providers.  Finally, the traditional healthcare delivery model requires 
face-to-face interactions between patients and providers.  The provider 
must actually see and speak to the patient in order to deliver the service.  
Thus, despite telemedicine, which still requires “face-to-face” contact, 
the traditional healthcare delivery model faces vast institutional barriers 
to meeting modern consumer needs. 
These challenges highlight the overarching problem with the 
traditional model: patients must spend a lot of time and money to get 
treatment.  Millennials are not buying into the traditional healthcare 
delivery model because it directly contradicts the qualities of service 
they value—namely efficiency and access.  While proponents of the 
traditional model may not see that demand in the market is shifting 
away for precisely this reason, direct-to-consumer advertisers and tech 
companies have taken note. 
III. CONCEPTUALIZING POSSIBLE SOLUTIONS TO PROTECT THE 
PATIENT-CONSUMER 
Despite the direct-to-consumer health market being highly 
saturated and profitable,111 the traditional healthcare industry is failing 
to capitalize on it.  As a result, a major patient-consumer demographic, 
Millennials, has drifted from the traditional model and fully embraced 
new technology that can resolve their medical concerns.  Most other 
                                                          
110. See generally Boodman, supra note 58. 
111. “In 2012, there were 828 companies in the high tech medical device 
industry, generating over an estimated $60 billion[.]”  Ciopraga, supra note 39, at 46. 
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industries have incorporated a direct-to-consumer strategy to increase 
profits and capitalize on this shift, but the traditional healthcare model 
may be unable to adapt.112  Unfortunately, in many ways current policy 
makes changing to a direct-to-consumer model impracticable. 
A. Retroactive Responses 
The amount of money funneled into the healthcare industry should 
convince lawmakers to get out ahead of these inevitable changes in the 
market, as, in reality, major changes have already taken place.  Instead, 
the government’s actions have handicapped the traditional healthcare 
industry’s ability to embrace these shifts.  To address this problem, 
legislators should reflect on these market changes, and adopt 
appropriate legislation.  Specifically, they should take an honest look at 
the hurdles the industry currently faces in its attempts to deliver 
adequate care under the traditional model—the most significant of 
which is cost. 
Many Americans consider the cost of healthcare to be one of the 
most important public policy concerns.113  While the ACA attempted to 
address consumer costs, unfortunately it did not go far enough.  This is 
likely because the healthcare industry is complex, entangled with many 
other institutions and markets. 
1. Medical Education 
The problems with healthcare costs start at the beginning, as 
specialty healthcare education is highly expensive and takes a long time 
to complete.  Additionally, a newly minted medical school graduate is 
paid very little when completing residency programs required to 
                                                          
112. “With millennials representing the largest living generation, having now 
surpassed baby boomers in total population, new patterns of purchasing and social 
behavior are emerging that seem likely to change insurers that try to hold to tried-and-
true marketing practices.”  Rieman, supra note 8. 
113. Exit polling following the 2018 midterm elections indicated the majority 
of voters felt health care was “very important” in making their voting decisions and a 
quarter indicated it was their “most important issue.”  Ashley Kirzinger et. al., 2018 
Midterms, KFF (Oct. 18, 2018), https://www.kff.org/health-reform/poll-finding/kff-
election-tracking-poll-health-care-in-the-2018-midterms. 
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specialize in a desired field.114  Depending on the specialty, residency 
can range from two to seven years.115  During that time, the majority of 
physicians are unable to pay back their federal loans, as their income 
does not meet the cost of required living expenses.116  Medical school 
students and residents are told that they will eventually be compensated 
for their time, and it is well known that doctors are generously 
compensated once they actually complete the training process.117 
As the traditional healthcare model depends heavily on the services 
provided by doctors, reducing these early costs would go far to reduce 
the impact on the consumer.  One possible solution would be for 
medical schools to consider making adjustments to expedite the 
learning process.  This would in turn expedite “onboarding” of 
physicians into the medical profession.  There are other fields that train 
medical professionals without being fundamentally economically 
inefficient.  For example, physician assistant programs appropriately 
train people without hobbling them with decades of unavoidable 
debt.118  Training programs for healthcare professionals should 
                                                          
114. Based on a 2018 report, despite most residents working over 60 hours per 
week, the average salary for their first-year was $55,200.  See Sandra Levy, Medscape 
Residents Salary & Debt Report 2018, MEDSCAPE (July 18, 2018), https://www.meds 
cape.com/slideshow/2018-residents-salary-debt-report-6010044#8.  
115. The residency follows an internship year. Jennifer Whitlock, Doctors, 
Residents, Interns, and Attendings: What’s the Difference, VERY WELL HEALTH (Oct. 
31, 2018), https://www.verywellhealth.com/types-of-doctors-residents-interns-and-
fellows-3157293. 
116. Nearly half of all medical students graduate with medical school debt 
exceeding $200,000; 23% have debt exceeding $300,000.  Levy, supra note 114. 
117. In 2018, the median household income in the United States was $62,175. 
June 2018 Median Household Income, SEEKING ALPHA, https://seekingalpha.com/ 
article/4193310-june-2018-median-household-income (last visited May 1, 2019).  
The average salary for a single American physician in 2018 was $299,000. The 
Highest-Paid Doctors (and the Lowest), According to Medscape, ADVISORY BOARD 
(Sept. 5, 2018), https://www.advisory.com/daily-briefing/2018/04/11/physician-co 
mpensation [hereinafter According to Medscape]. 
118. Physician Assistants (“PA”) earn a Master’s Degree after two to three years 
of coursework.  Most schools suggest the PA curriculum is extremely similar to the 
“in class” curriculum taken by medical doctors.  To earn a Doctorate in Medicine a 
medical student is required to complete eight-week clinical rotations in each specialty 
in their final two years of medical school before choosing a residency program.  
However, PA’s are eligible to begin work as soon as they meet their state 
qualifications.  Similar to residency, PA’s gain their specialized experience on the job. 
Sophie Cresswell, What is the Difference Between a Doctor and a Physician 
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reconsider their pedagogical models and examine ways to cut costs or 
reduce the time it takes to complete a degree in an effort to reduce 
overall healthcare costs. 
2. Service Costs 
Service costs are extraordinarily inflated in the United States.  This 
is largely a reflection of administrative overhead and healthcare 
professionals’ salaries.  Unlike most industries that compensate based 
on promotional structure, healthcare compensates based on level of 
specialty and billed services.119  This “fee for service” model drives up 
cost of pay for the average patient, but most doctors fail to accept 
responsibility for the cost of healthcare in the United States.120 
Furthermore, the market for healthcare services does not reflect 
consumer demand.  Unlike most industries where costs are driven down 
by competition, health service and pharmaceutical costs in the United 
States are driven up as insurers negotiate pricing with for-profit hospital 
systems and pharmaceutical companies directly.121  These costs 
eventually fall back on the patient; as a result, every aspect of the 
provider visit costs more in the United States than anywhere else in the 
world.122  It is no surprise that patients – especially Millennial patients 
who are the least likely to invest in healthcare – are willing to consider 
other available options in an effort to circumvent this system. 
                                                          
Assistant?, GAPMEDICS: BLOG (Oct. 16, 2013), https://www.gapmedics.com/blog 
/2013/10/16/what-is-the-difference-between-a-doctor-and-a-physicians-assistant. 
119. Within the last year, physicians saw an average compensation increase 
ranging from 9-16%.  Based on a 2018 Medscape survey, the average salary for non-
specialty preventive care physicians (pediatricians, family medicine, and internal 
medicine) is $220,000.  The highest salary for a specialty physician (Plastic Surgery) 
is $501,000.  The lowest average salary for a specialty physician (Endocrinology) is 
$212,000.  According to Medscape, supra note 117; see also Jacquelyn Smith, The 
Best and Worst – Paying Jobs for Doctors, FORBES (July 20, 2012, 4:45 PM), 
https://www.forbes.com/sites/jacquelynsmith/2012/07/20/the-best-and-worst-paying 
-jobs-for-doctors-2/#1c28b1eba2a3. 
120. Robert Pearl, Healthcare’s Dangerous Fee-for-Service Addiction, FORBES 
(Sept. 25, 2017, 12:55 PM), https://www.forbes.com/sites/robertpearl/2017/09/25/fee 
-for-service-addiction/#1e89a742c8ad. 
121. See Kliff, supra note 30. 
122. Blumberg, supra note 10. 
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As the market forces affecting healthcare costs cut against the 
consumer, and the cost of healthcare is driving consumers to options 
not yet embraced by the traditional healthcare model, decision makers 
should pay attention.  Specifically, hospital administrators should 
consider implementing available direct-to-consumer tools that fit 
within the current model – such as telemedicine, mHealth, and online 
pharmacies – in an effort to decrease service costs. 
3. Pharmaceutical Drug Costs 
Insurance companies and Congress should reconsider their 
reimbursement model and realistically reform the costs of patient care 
and pharmaceuticals.  While lawmakers have examined numerous 
methods to successfully combat the rising cost of prescription drugs in 
the United States, the most impactful solution that has been proposed 
would expand the price negotiation power of Medicare.123  Some 
experts believe that allowing Medicare to negotiate drug prices with 
pharmaceutical companies would save the government $15 billion a 
year.124  This would also drive down costs of drugs taken by non-
government insurance policy holders, as insurance companies often 
look to Medicare for benchmark pricing when negotiating costs. 
Nevertheless, this solution has met its fair share of criticism.  
Patient advocacy groups fear that providing the government extended 
oversight into the pharmaceutical industry will decrease patient access 
to new drugs and disincentivize innovation.125  Furthermore, 
pharmaceutical companies directed significant financial resources 
toward lobbying Congress in an effort to exclude this policy from the 
ACA.126  As a result, lawmakers are instead focusing on incrementally 
addressing the public’s concerns through less impactful policies, 
including pressuring companies to set lower prices.127 
The current administration has proposed the most comprehensive 
effort yet to address prescription costs with a plan entitled “American 
                                                          
123. See Rena M. Conti & Meredith B. Rosenthal, Pharmaceutical Policy 
Reform – Balancing Affordability With Incentives for Innovation, 374 NEW ENGLAND 
J. MED. 703, 704 (2016).  
124. Id. 
125. Id. 
126. Id. (citing Daemmrich, supra note 14). 
127. Id. at 704–05. 
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Patients First.”128  Under this plan, the Department of Health and 
Human Services (HHS) has identified challenges in the American drug 
market and isolated goals for reform including improving competition 
and enabling cost negotiation.129 
Under this plan, by lifting  previously imposed barriers and shifting 
coverage of medications between sectors, Medicare will be able to 
negotiate the cost of physician-administered medications.130  These 
subtle changes may achieve the outcome American’s are hoping for, 
but only if Congress is willing to revisit the laws that are responsible 
for driving up prescription drug costs in the first place.131  While this 
proposition is a step in the right direction, it fails to address any solution 
to make medications more affordable by focusing primarily on 
increasing competition.132  While the plan discusses the influence of 
increased competition on the prices of the medications,133 it fails to 
address how the plan will actually attack the price of the medication 
itself.  Experts believe failing to focus on decreasing the net price of 
prescription medications undermines the potential positive effects of 
the proposed legislation. 
Though policy makers seem to be interested in addressing the 
significant weaknesses in our current healthcare system, as of yet few 
                                                          
128. DEP’T OF HEALTH & HUMAN SERVICES, AMERICAN PATIENTS FIRST: THE 
TRUMP ADMINISTRATION BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT-OF-
POCKET COSTS 9 (2018). 
129. “HHS has identified four challenges in the American drug market: high list 
prices for drugs; seniors and government programs overpaying for drugs due to lack 
of the latest negotiation tools; high and rising out-of-pocket costs for consumers; [and] 
foreign governments free-riding off of American investment in innovation.”  Id. 
130. On August 7, 2018, U.S. Health and Human Services Secretary Alex Azar 
announced President Trump’s plan to reduce high prescription drug prices by 
establishing a number of solutions to enhance competition among retail and hospital 
administered drugs in an effort to bring drug prices down.  Avik Roy, Trump’s New 
Medicare Rule to Reduce Prescription Drug Prices Through Competition, FORBES: 
THE APOTHECARY (Aug. 7, 2018 9:44 PM), https://www.forbes.com/sites/the 
apothecary/2018/08/07/trumps-new-medicare-rule-to-reduce-prescription-drug-price 
s-through-competition/#29d4746f7e88.  
131. These include the Orphan Drug Act of 1983 which allows companies with 
no intellectual property to charge high prices for drugs used to treat rare diseases, and 
the Biologics Price, Competition, and Innovation Act of 2009 which has not done 
enough to encourage competition for off-patent biotech drugs. 
132. See Roy, supra note 130. 
133. Id. 
27
Levy: Marketing Medicine to Millennials: Preparing Institutions and Reg
Published by CWSL Scholarly Commons, 2019
Mollie Levy camera ready FINAL (Do Not Delete) 7/10/2019  9:10 AM 
548 CALIFORNIA WESTERN LAW REVIEW [Vol. 55 
truly effective solutions have been put in place.  Moreover, the 
traditional healthcare industry has not taken steps to adapt to the 
imminent changes in the marketplace and prevent these historical 
shortfalls from being inevitably exacerbated.  Policy makers should 
take an honest, comprehensive look back at the things that have not 
been working in the healthcare industry and change course now before 
it is too late. 
B. Proactive Reform 
Alternatively – and perhaps more realistically – we should look to 
trends in other industries as a model for legislative reform in an effort 
to protect and propel the healthcare industry as it braces for change.  
Despite the value in reflecting on past successes or failures, perhaps it 
would also be valuable to consider the hurdles the industry will face as 
the industry embraces direct-to-consumer health methods. 
As discussed above, if history repeats itself, big tech companies 
will change the way we receive healthcare.  Many other industries have 
been disrupted by direct-to-consumer strategies in this way, and 
healthcare is likely next.134  Thus, for the traditional healthcare delivery 
model to survive, the industry should adopt strategies that have proved 
effective in other sectors.  In essence, the patient should be viewed as a 
consumer and the service should be redefined as a product. 
1. The FTC and HIPAA 
Traditionally, legislatures are less restrictive in terms of oversight 
over the sale of goods versus the implementation of services.  This 
distinction is illustrated in the healthcare industry by Congress’s 
willingness to embrace the sale of drugs online, and simultaneous 
refusal to reimburse medical visits performed online; Congress allowed 
for online pharmacies nearly a decade before addressing 
telemedicine.135  While HIPAA currently protects patient information 
in a traditional setting, it has not been adjusted to protect patient 
                                                          
134. Tech Bets, supra note 49. 
135. Compare 21 U.S.C. § 831 (2009), with 38 U.S.C. § 1730C (2018). 
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information in a non-traditional, direct-to-consumer context.136 To 
reconcile this contradiction, healthcare oversight should be adjusted, 
namely how FTC in HIPAA regulations operate, to allow the traditional 
healthcare industry to incorporate alternative delivery options. 
2. mHealth Regulation 
Though the capabilities of mHealth apps continue to evolve, 
government regulation has not kept up.  Consequently, users are left 
exposed to privacy risks and being misled by overpromising, 
unregulated applications.137  To bring mHealth under the ambit of 
current consumer protections, healthcare reform should allow hospitals 
to implement direct-to-consumer options like mHealth. 
Experts predict hospitals could save over $300 billion in 
administrative costs a year by implementing mHealth apps on a large 
scale by “reducing travel time and improving communication of 
medical decisions.”138  The use of mHealth apps will also “reduce 
emergency room visits and hospital readmissions [by providing] timely, 
efficient, and effective care management” as an alternative to relying 
solely on the traditional treatment scheme.139  Capitalizing on this 
delivery system could help keep healthcare dollars contained within the 
traditional delivery model. 
As mHealth and other emerging technologies are already 
revolutionizing the healthcare industry, the strategies put in place now 
to cope with these inevitable changes are critically important.  The gaps 
and overlaps in regulatory measures that place a yoke on traditional 
healthcare institutions’ abilities to modernize by utilizing these 
technologies are thus ripe for reconsideration. 
                                                          
136. “The dichotomy between the highly regulated HIPAA zone and the lightly 
regulated external zone is a function of the sectoral approach to data protection in the 
United States.”  Terry, supra note 21, at 339. 
137. Ovansian, supra note 88, at 174. 
138. Flaherty, supra note 76, at 420. 
139. Barry Liss, HIPAA and Mobile Health: Where’s the App for That, 34 
COMPUTER & INTERNET LAW. 9, 9 (2017). 
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3. Monopoly Oversight 
Finally, the legislature should take a hard look at the potential 
monopolization of healthcare by big tech companies that are already 
consolidating emerging, unregulated markets, and which will likely 
develop their own healthcare systems.  Companies like Amazon and 
Google are shifting their focus to health in an effort to resolve all the 
problems the American consumer faces when it comes to care.140 
In 2018, Google launched a health initiative to monetize “its 
profitable search and business proficiencies within the world of 
healthcare[.]”141 Moreover, Google’s newest member of its executive 
team Dr. David Feinberg is an advocate for bringing care out of the 
medical facility and into the home.142  Previously referring to hospitals 
as “Blockbuster,” Dr. Feinberg predicts 50% of today’s inpatient 
medical services “will soon be rendered in people’s homes, and without 
the many risks associated with a hospital stay.”143  The traditional 
healthcare model is no match for the energy and resources of big tech. 
Without embracing this shift in care, the American consumer will 
watch these tech companies swallow up the largest hospital systems in 
the country.144  Thus, for the traditional healthcare delivery model to 
survive the current and future disruptions within the industry, and avoid 
companies like Amazon and Google overtaking them, serious 
regulatory reform is needed. 
CONCLUSION 
While Congress continues its partisan battles over healthcare 
reform, it is failing to see the forest through the trees and missing the 
clear shift within the industry.  Tragically, those in need of healthcare 
are the ones that will continue to suffer.  As nearly all products and 
services available to the American consumer today have, the healthcare 
industry will likely shift substantially into different delivery models.  
Millennials’ expectation of direct-to-consumer purchasing, in 
                                                          
140. Tech Bets, supra note 49. 
141. Pearl, supra note 1. 
142. Id. 
143. Id. 
144. C.f. Taylor, Hanbury, & Green, supra note 51.  
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combination with the $3.5 trillion incentive,145 makes this shift 
practically inevitable.  Over the next decade, the patient will become 
the consumer, and today the patient-consumer has no place in 
traditional healthcare delivery. 
The writing is on the wall, our healthcare system is fundamentally 
unprepared for the change that is coming.  The patchwork of 
inconsistent regulation and selectivity of legislative priorities have left 
the American consumer of healthcare out in the cold.  The maneuvering 
of big tech companies, the proliferation of online pharmacies, and the 
emergence of opportunistically unregulated medical devices all point to 
one thing – action is needed now.  As with many of the partial solutions 
currently in place, the critical issues our healthcare system will face in 
the coming years will only pass on more costs to consumers if 
something is not done to resolve them. 
Legislators need to reconcile the gaps in regulation that are 
currently being exploited and plan ahead for market shifts that will 
inevitably affect the rights and pocketbooks of patients.  Decision 
makers within the healthcare industry should take both internal action 
to deal realistically with costs, taking into account their need to 
modernize, and lobby for external actions to modulate the imminent 
disruption of their industry.  The purpose of having a healthcare system 
in the first place is to ensure that patients can get the care they need.  Of 
course, this need must be balanced with economic interests of 
institutions engaged in the business of providing care.  However, 
without thoughtful and comprehensive action to head off the dynamics 
emerging in our current system, the American consumer of healthcare 
will continue to bare ever increasing costs.  Change is coming—and 
change is needed. 
Mollie Levy* 
                                                          
145. See Pearl, supra note 1.  
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